Well let’s face it. Primary Care is dead in 2 years. They’ll actually adjust in 2020. Viberzi is a complete dog and not very profitable. Vrylar isn’t making much and won’t. Too many options with better side effect profile that are generic. Viibryd is barely marketed, Namzaruc is obviously dead. There’s NOTHING in the pipleline for us except except the antidepressant which could be a game changer or another total let down depending on study results.
Linzess if the only bright spot.
Will PC be sold off or just another headcount reduction?
We are about to be down to Linzess and hopefully the anti-depressant
Linzess if the only bright spot.
Will PC be sold off or just another headcount reduction?
We are about to be down to Linzess and hopefully the anti-depressant